公开(公告)号：US5922767A

公开(公告)日：1999-07-13

申请号：US946098

申请日：1997-10-07

申请人： Yoshihiko Kanamaru ,  Hiroyuki Hirota ,  Akihiro Shibata ,  Teruo Komoto ,  Hiroyuki Naito ,  Koichi Tachibana ,  Mari Ohtsuka ,  Fumio Ishii ,  Susumu Sato

发明人： Yoshihiko Kanamaru ,  Hiroyuki Hirota ,  Akihiro Shibata ,  Teruo Komoto ,  Hiroyuki Naito ,  Koichi Tachibana ,  Mari Ohtsuka ,  Fumio Ishii ,  Susumu Sato

IPC分类号： C07C275/28 ,  C07D213/30 ,  C07D307/42 ,  C07D333/16 ,  A61K31/17 ,  C07C275/06

CPC分类号： C07D213/30 ,  C07C275/28 ,  C07D307/42 ,  C07D333/16

摘要： Disclosed herein are substituted benzylurea derivatives represented by the following general formula (1): ##STR1## wherein R.sup.1 and R.sup.2 are independently H, a halogen atom, or an alkyl or alkoxyl group, R.sup.3 is a phenyl or heterocyclic group which may be substituted, n is an integer of 1-6, and R.sup.4 is a phenyl group which may be substituted, or salts thereof, and medicines comprising such a derivative as an active ingredient. The derivatives or salts thereof strongly inhibit only ACAT in macrophages and are hence useful as prophylactic and therapeutic agents for arteriosclerosis.

摘要翻译： 本文公开了由以下通式（1）表示的取代的苄基脲衍生物：其中R 1和R 2独立地为H，卤素原子或烷基或烷氧基，R 3为可被取代的苯基或杂环基，n为 1-6的整数，R4是可被取代的苯基或其盐，以及包含这种衍生物作为活性成分的药物。 其衍生物或盐在巨噬细胞中仅强烈地抑制ACAT，因此可用作动脉硬化的预防和治疗剂。

公开(公告)号：US5866609A

公开(公告)日：1999-02-02

申请号：US899647

申请日：1997-07-24

申请人： Yoshihiko Kanamaru ,  Hiroyuki Hirota ,  Akihiro Shibata ,  Teruo Komoto ,  Hiroyuki Naito ,  Koichi Tachibana ,  Mari Ohtsuka ,  Fumio Ishii ,  Susumu Sato

发明人： Yoshihiko Kanamaru ,  Hiroyuki Hirota ,  Akihiro Shibata ,  Teruo Komoto ,  Hiroyuki Naito ,  Koichi Tachibana ,  Mari Ohtsuka ,  Fumio Ishii ,  Susumu Sato

IPC分类号： C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C275/40 ,  C07C275/42 ,  C07C317/42 ,  C07C323/44 ,  C07D211/58 ,  C07D317/58 ,  C07D317/66 ,  A61K31/17 ,  C07C275/04

CPC分类号： C07C317/42 ,  C07C275/28 ,  C07C275/30 ,  C07C275/34 ,  C07C275/40 ,  C07C275/42 ,  C07C323/44 ,  C07D211/58 ,  C07D317/58 ,  C07D317/66 ,  C07C2101/14

摘要： Disclosed herein are substituted vinylurea derivatives represented by the following general formula (1): ##STR1## wherein R.sup.1 and R.sup.3 are independently a phenyl group which may be substituted, R.sup.2 is a phenyl group which may be substituted, or a cycloalkyl group, and wave lines mean that the bonding state may be either E or Z, with the proviso that the cases where R.sup.1, R.sup.2 and R.sup.3 are unsubstituted phenyl groups, and where R.sup.1 and R.sup.2 are unsubstituted phenyl groups and R.sup.3 is a 4-ethoxyphenyl group are excluded, or salt thereof, and medicines comprising such a derivative as an active ingredient as well as a method of preventing and treating arteriosclerosis with such a medicine. The derivatives or salts thereof selectively and strongly inhibit ACAT in macrophages and are hence useful as prophylactic and therapeutic agents for arteriosclerosis.

摘要翻译： 本文公开了由以下通式（1）表示的取代的乙烯基脲衍生物：其中R 1和R 3独立地为可被取代的苯基，R 2为可被取代的苯基或环烷基 并且波线意味着键合状态可以是E或Z，条件是其中R1，R2和R3是未取代的苯基，R1和R2是未取代的苯基，R3是4-乙氧基苯基的情况 或其盐，以及包含这样的衍生物作为活性成分的药物，以及用这种药物预防和治疗动脉硬化的方法。 其衍生物或其盐在巨噬细胞中选择性且强烈地抑制ACAT，因此可用作动脉硬化的预防和治疗剂。

公开(公告)号：US6071943A

公开(公告)日：2000-06-06

申请号：US200750

申请日：1998-11-30

申请人： Noriaki Shioiri ,  Tadashi Mikami ,  Shinichi Morimoto ,  Kazuo Yamazaki ,  Hiroyuki Naito ,  Junji Okawa ,  Noriyuki Kawamoto ,  Hiroshi Hasegawa ,  Koichi Tachibana ,  Susumu Sato ,  Toshio Yokoyama

发明人： Noriaki Shioiri ,  Tadashi Mikami ,  Shinichi Morimoto ,  Kazuo Yamazaki ,  Hiroyuki Naito ,  Junji Okawa ,  Noriyuki Kawamoto ,  Hiroshi Hasegawa ,  Koichi Tachibana ,  Susumu Sato ,  Toshio Yokoyama

IPC分类号： C07D233/54 ,  C07D233/64 ,  C07D233/70 ,  C07D405/12 ,  A01N43/50

CPC分类号： C07D233/64 ,  C07D405/12

摘要： Disclosed herein are an imidazole derivative represented by the following general formula (1): ##STR1## wherein R.sup.1 is a hydrogen atom, or an alkyl, alkoxy or alkoxycarbonyl group, and R.sup.2, R.sup.3 and R.sup.4 are the same or different from one another and are independently a hydrogen or halogen atom, an alkyl, halogenoalkyl, hydroxyl or alkoxy group, or the like, or a salt thereof, and a medicine comprising such a compound. The compound specifically suppresses the production of particular cytokine and is hence useful as an active ingredient for immune function modulators and the like.

摘要翻译： 本文公开了由以下通式（1）表示的咪唑衍生物：其中R1是氢原子或烷基，烷氧基或烷氧基羰基，R2，R3和R4彼此相同或不同，独立地为 氢或卤素原子，烷基，卤代烷基，羟基或烷氧基等，或其盐，以及包含这种化合物的药物。 该化合物特别抑制特定细胞因子的产生，因此可用作免疫功能调节剂等的活性成分。

公开(公告)号：US20230036748A1

公开(公告)日：2023-02-02

申请号：US17933207

申请日：2022-09-19

申请人： Kohsuke Miyazaki ,  Hiroyuki Naito ,  Takumi Yokoyama ,  Junjiroh Sogame ,  Shinichiroh Satoh ,  Naoki Oya ,  Katsuhiko Fujii

发明人： Kohsuke Miyazaki ,  Hiroyuki Naito ,  Takumi Yokoyama ,  Junjiroh Sogame ,  Shinichiroh Satoh ,  Naoki Oya ,  Katsuhiko Fujii

IPC分类号： B29C64/165 ,  B33Y10/00 ,  B33Y70/10 ,  B22F10/14 ,  B28B1/00 ,  B33Y80/00 ,  C09D133/14 ,  C09D131/02 ,  C09D175/04 ,  C09D139/06 ,  C09D161/04

摘要： Provided is a three-dimensional object producing method that includes applying an object forming liquid to powder including a base material and an organic material to form a solidified product, and removing the powder deposited on the solidified product from the solidified product using a powder removal liquid including an organic solvent. The following formulae are satisfied RED of non-forming part 0.55. The forming part is a portion of the powder to which the object forming liquid is applied and RED of the forming part is a distance between HSP of the forming part and HSP of the organic solvent. The non-forming part is a portion of the powder to which the object forming liquid is not applied and RED of the non-forming part is a distance between HSP of the non-forming part and HSP of the organic solvent.

公开(公告)号：US10584194B2

公开(公告)日：2020-03-10

申请号：US15629955

申请日：2017-06-22

申请人： Hiroshi Iwata ,  Yoshihiro Norikane ,  Tatsuya Niimi ,  Takashi Matsumura ,  Hiroyuki Naito

发明人： Hiroshi Iwata ,  Yoshihiro Norikane ,  Tatsuya Niimi ,  Takashi Matsumura ,  Hiroyuki Naito

IPC分类号： C08F2/50 ,  C08F2/48 ,  C08G61/04 ,  C08F20/16 ,  C09D11/101 ,  C09D11/30 ,  B29C64/112 ,  C08J3/075

摘要： An active energy ray liquid composition is provided. A cured product of the active energy ray curable liquid composition is a solid at 25° C. and a liquid at 60° C., and the solid exhibits a compression stress of 2.0 kPa or more when compressed 1%.

公开(公告)号：US20180345036A1

公开(公告)日：2018-12-06

申请号：US16058527

申请日：2018-08-08

申请人： Tatsuya NIIMI ,  Yoshihiro Norikane ,  Takashi Matsumura ,  Hiroshi Iwata ,  Hiroyuki Naito

发明人： Tatsuya NIIMI ,  Yoshihiro Norikane ,  Takashi Matsumura ,  Hiroshi Iwata ,  Hiroyuki Naito

IPC分类号： A61N5/10 ,  A61K41/00 ,  B33Y80/00

CPC分类号： A61N5/10 ,  A61K41/0038 ,  A61N2005/1096 ,  B33Y10/00 ,  B33Y80/00

摘要： Provided is a bolus formed of a hydrogel, wherein the hydrogel includes water, a polymer, and a mineral, and wherein the bolus is applied to a patient who receives a radiation therapy.

公开(公告)号：US08404691B2

公开(公告)日：2013-03-26

申请号：US13183762

申请日：2011-07-15

申请人： Kouichi Uoto ,  Yuuichi Sugimoto ,  Hiroyuki Naito ,  Masaki Miyazaki ,  Keisuke Yoshida ,  Masashi Aonuma

发明人： Kouichi Uoto ,  Yuuichi Sugimoto ,  Hiroyuki Naito ,  Masaki Miyazaki ,  Keisuke Yoshida ,  Masashi Aonuma

IPC分类号： A61K31/496 ,  C07D513/04

CPC分类号： A61K31/499 ,  C07D513/04

摘要： There is provided compounds that inhibit interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. Compounds include imidazothiazole derivatives that can inhibit interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity.

摘要翻译： 提供了抑制鼠双分钟2（Mdm2）蛋白和p53蛋白之间的相互作用并表现出抗肿瘤活性的化合物。 化合物包括可以抑制Mdm2蛋白和p53蛋白之间的相互作用并表现出抗肿瘤活性的咪唑并噻唑衍生物。

公开(公告)号：US07576135B2

公开(公告)日：2009-08-18

申请号：US10540259

申请日：2003-12-25

申请人： Toshiharu Ohta ,  Satoshi Komoriya ,  Toshiharu Yoshino ,  Kouichi Uoto ,  Yumi Nakamoto ,  Hiroyuki Naito ,  Akiyoshi Mochizuki ,  Tsutomu Nagata ,  Hideyuki Kanno ,  Noriyasu Haginoya ,  Kenji Yoshikawa ,  Masatoshi Nagamochi ,  Syozo Kobayashi ,  Makoto Ono

发明人： Toshiharu Ohta ,  Satoshi Komoriya ,  Toshiharu Yoshino ,  Kouichi Uoto ,  Yumi Nakamoto ,  Hiroyuki Naito ,  Akiyoshi Mochizuki ,  Tsutomu Nagata ,  Hideyuki Kanno ,  Noriyasu Haginoya ,  Kenji Yoshikawa ,  Masatoshi Nagamochi ,  Syozo Kobayashi ,  Makoto Ono

IPC分类号： A61K31/13

CPC分类号： C07D498/04 ,  C07D213/75 ,  C07D401/12 ,  C07D401/14 ,  C07D409/04 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D513/14 ,  C07D519/00

摘要： A compound represented by formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4  (1) [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

摘要翻译： Q1-Q2-T0-N（R1）-Q3-N（R2）-T1由式（1）表示的化合物：<？in-line-formula description =“In-line formula”end =“lead” -Q4（1）<？in-line-formula description =“In-line Formulas”end =“tail”？> [其中R1和R2是氢原子等; Q1是可以被取代的饱和或不饱和的5或6元环烃基，等等; Q2是单键等; Q3表示以下基团：（其中Q5为碳原子数为1〜8的亚烷基等）; 并且T0和T1是羰基等]，其盐，其溶剂合物或其N-氧化物。 该化合物可用作预防和/或治疗脑梗塞，脑栓塞，心肌梗死，心绞痛，肺梗塞，肺栓塞，Buerger病，深静脉血栓形成，弥散性血管内凝血综合征，人工瓣膜或关节后血栓形成 血管成形术后的替代，血栓形成和再闭塞，全身炎症反应综合征（SIRS），多器官功能障碍综合征（MODS），体外循环期间的血栓形成或血液抽血时的凝血。

公开(公告)号：US20070129371A1

公开(公告)日：2007-06-07

申请号：US10539995

申请日：2003-12-24

申请人： Yumi Nakamoto ,  Toshiharu Yoshino ,  Hiroyuki Naito ,  Tsutomu Nagata ,  Kenji Yoshikawa ,  Makoto Suzuki

发明人： Yumi Nakamoto ,  Toshiharu Yoshino ,  Hiroyuki Naito ,  Tsutomu Nagata ,  Kenji Yoshikawa ,  Makoto Suzuki

IPC分类号： A61K31/519 ,  A61K31/503 ,  A61K31/501 ,  A61K31/517 ,  A61K31/497 ,  A61K31/498

CPC分类号： C07D417/12 ,  C07D213/75

摘要： A compound represented by the following formula (1): Q1—Q2—To—N(R1)—Q3—N(R2)—T1—Q4  (1) [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: —C(R3a)(R4a)—{C(R3b)(R4b)}m1—{C(R3c)(R4c)}m2—{C(R3d)(R4d)}m3—{C(R3e)(R4e)}m4—C (R3f)(R4f)— (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents —COCONR— or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

公开(公告)号：US20050227429A1

公开(公告)日：2005-10-13

申请号：US10508460

申请日：2003-03-27

申请人： Shozo Minamitani ,  Takaharu Mae ,  Yasuharu Ueno ,  Akira Yamada ,  Shinji Kanayama ,  Makoto Akita ,  Nobuhisa Watanabe ,  Akira Mori ,  Hiroyuki Naito ,  Shinya Marumo ,  Makoto Morikawa

发明人： Shozo Minamitani ,  Takaharu Mae ,  Yasuharu Ueno ,  Akira Yamada ,  Shinji Kanayama ,  Makoto Akita ,  Nobuhisa Watanabe ,  Akira Mori ,  Hiroyuki Naito ,  Shinya Marumo ,  Makoto Morikawa

IPC分类号： B23K20/10 ,  H01L21/00 ,  H01L21/8238

CPC分类号： H01L24/81 ,  B23K20/10 ,  B23K2101/40 ,  H01L21/67144 ,  H01L24/75 ,  H01L2224/75 ,  H01L2224/75252 ,  H01L2224/75355 ,  H01L2224/75743 ,  H01L2224/81205 ,  H01L2224/8121 ,  H01L2224/81222 ,  H01L2224/81224 ,  H01L2224/81815 ,  H01L2924/01005 ,  H01L2924/01033 ,  H01L2924/01047 ,  H01L2924/01082 ,  H01L2924/014 ,  H01L2924/12042 ,  H01L2924/14 ,  H01L2924/00

摘要： A component mounting apparatus includes a component feeder (20) that feeds a component (2) with its bump electrodes facing down, a mounting head (5) that mounts the component onto a substrate (3), a supporting base (8) that secures the substrate, and a positioning device (6, 7) that aligns the component with the substrate. The mounting head includes an ultrasonic vibration generator (24), an ultrasonic vibration propagation member (34, 38, 54) that conveys the ultrasonic vibration provided by the ultrasonic vibration generator to a working face (33, 41, 57) holding the component as vibration parallel thereto, a pressure loader (22, 23, 39, 55, 59) that applies a pressure load to the working face from a position immediately thereabove in the direction perpendicular thereto, and a heater (32, 47, 49, 50, 51, 52, 53) that heats the vicinity of the working face. Thereby, ultrasonic bonding is carried out with high reliability even if the component has a number of bump electrodes (2a) on its face.

摘要翻译： 一种部件安装装置，包括：一个部件供给器（20），其部件（2）的凸起电极朝下;一个安装头（5），该部件安装在基板（3）上;支撑基座（8） 所述基板以及将所述部件与所述基板对准的定位装置（6,7）。 安装头包括超声波振动发生器（24），超声波振动传播部件（34,38,54），其将由超声波振动发生器提供的超声波振动传递到保持部件的工作面（33,41,57），如 振动平行的压力加载器（22,23,39,55,59），其从垂直于其垂直方向的上方的位置向工作面施加压力负荷;加热器（32,47,49,55,59） 51,52,53），其加热了工作面附近。 因此，即使该部件的面上具有多个凸块电极（2a），也可以高可靠性地进行超声波接合。